<DOC>
	<DOCNO>NCT02978495</DOCNO>
	<brief_summary>Breast cancer frequent neoplasm woman Brazil world 15 % case diagnose correspond triple negative subtype . Triple negative breast cancer affect young woman germline mutation BRCA 1/2 gene . Giving lack target therapy date , consensus regard effective treatment subgroup tumor . Although evidence show triple negative breast cancer highly sensitive chemotherapy compare breast tumor , evidence support hypothesis patient triple negative breast cancer mutation BRCA1 / 2 gene higher chemosensitivity neoadjuvant therapy . The investigator propose prospective , randomize , open-label , phase II study , evaluate rate complete pathologic response , disease-free survival , overall survival prognostic evaluation BRCA1 / 2 mutation status woman triple negative breast cancer submit sequential neoadjuvant chemotherapy base anthracycline taxane , without carboplatin .</brief_summary>
	<brief_title>Neoadjuvant Carboplatin Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Hereditary Breast Ovarian Cancer Syndrome</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Triple Negative Breast Cancer ; Stage II III ; Performance Status ECOG &lt; 2 Karnofsky &gt; 50 % ; Hematologic ( minimal value ) : Absolute neutrophil count &gt; 1,500/mm3 Hemoglobin &gt; 10.0 g/dl Platelet count &gt; 100,000/mm3 Stage I IV ; malignancy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>